Clinical Trial

Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms

Study acronym: Drug-SNP
Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
Explore the relationship between drug target topoisomerase I gene single nucleotide polymorphisms and Topotecan therapeutic-effects in patients with small cell lung cancer, based on Oxford precisely sequencing drug targets' genes. Explore the relationship between drug target CYP4503A4 gene single nucleotide polymorphisms and Topotecan side-effects in patients with small cell lung cancer, based on Oxford precisely sequencing drug targets' genes.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-25.
Trial Details
NCT Number NCT07145333
Lead Sponsor Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Collaborators: UnitedHealthcare
Conditions SCLC
Enrollment 600 participants
Start Date 2025-08-12
Primary Completion 2026-09-18 (estimated)
Study Completion 2026-10-28 (estimated)
Updated on ClinicalTrials.gov 2025-09-08